- Home
- LCFY vs CHRO Comparison
LCFY vs CHRO Comparison
Compare LCFY & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCFY
- CHRO
- Stock Information
- Founded
- LCFY 2009
- CHRO 2002
- Country
- LCFY Australia
- CHRO United States
- Employees
- LCFY N/A
- CHRO N/A
- Industry
- LCFY
- CHRO
- Sector
- LCFY
- CHRO
- Exchange
- LCFY Nasdaq
- CHRO Nasdaq
- Market Cap
- LCFY 9.9M
- CHRO 11.3M
- IPO Year
- LCFY 2022
- CHRO 2024
- Fundamental
- Price
- LCFY $8.40
- CHRO $1.68
- Analyst Decision
- LCFY
- CHRO Strong Buy
- Analyst Count
- LCFY 0
- CHRO 1
- Target Price
- LCFY N/A
- CHRO N/A
- AVG Volume (30 Days)
- LCFY 18.2K
- CHRO 104.9K
- Earning Date
- LCFY 04-01-2025
- CHRO 03-04-2025
- Dividend Yield
- LCFY N/A
- CHRO N/A
- EPS Growth
- LCFY N/A
- CHRO N/A
- EPS
- LCFY N/A
- CHRO N/A
- Revenue
- LCFY $2,668,385.00
- CHRO N/A
- Revenue This Year
- LCFY N/A
- CHRO N/A
- Revenue Next Year
- LCFY N/A
- CHRO N/A
- P/E Ratio
- LCFY N/A
- CHRO N/A
- Revenue Growth
- LCFY N/A
- CHRO N/A
- 52 Week Low
- LCFY $2.20
- CHRO $0.45
- 52 Week High
- LCFY $11.23
- CHRO $4.84
- Technical
- Relative Strength Index (RSI)
- LCFY 57.38
- CHRO 50.49
- Support Level
- LCFY $5.80
- CHRO $1.59
- Resistance Level
- LCFY $8.95
- CHRO $1.99
- Average True Range (ATR)
- LCFY 0.63
- CHRO 0.29
- MACD
- LCFY 0.13
- CHRO -0.06
- Stochastic Oscillator
- LCFY 82.54
- CHRO 41.44
About LCFY Locafy Limited
Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has two operating segments: Publishing and SEO agency. Under the Publishing segment are products and services that the Company offers that are related to digital properties (i.e. mastheads) that it owns e.g. business data published on Hotfrog, advertising placed on AussieWeb, articles published on scoop.com.au. In contrast, under the SEO Agency segment are products and services that are applied to digital properties that are owned and operated by third parties. It derives a majority of its revenue in North America from SEO Agency.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.